BTK and B-cell chronic lymphocytic leukemia: If safety concerns exist (e.g., patient has CV risk factors), one should favor more selective drugs like acalabrutinib or Zanubrutinib (although newer generation BTK inhibitors have now shown improved efficacy over ibrutinib in the relapse/refractory setting and are also approved for front-line CLL).